DATALYTYX
5.6.2020 11:12:06 CEST | Business Wire | Press release
Datalytyx today announced an expanded partnership with Snowflake , the Cloud Data Platform, that enables the next generation Datalytyx DataOps for Snowflake platform to be deployed for a 2 week trial on Snowflake . Customers can orchestrate the ingestion of data from many on-premise and cloud platforms via 3rd party data tools, model data easily, automatically test those models as part of their pipelines, launch AI/ML models and enable the consumption of data to deliver immediate stakeholder value.
As a great example, in the midst of the Coronavirus pandemic, BOC , the UK market-leading gas supply company for delivery of healthcare oxygen, has faced unprecedented demand, from equipping Nightingale hospitals to delivering O2 cylinders in homes. Datalytyx have deployed their DataOps for Snowflake platform to help BOC manage their cylinder stock and logistics data, for all types of gases, to increase production efficiency and provide best-in-class customer service.
“Datalytyx said they could get their DataOps Platform in and working within three weeks, and they did. What’s more, the capability it’s bringing us, to set up, monitor and amend data feeds simply and rapidly, is really quite transformational.”
David Galloway, Strategy and Business Insight Manager for BOC
And at wejo , the connected car company, they have been innovating in connected car data to create ground-breaking products and services that revolutionise the way people travel. By generating insights to harness the value of that data, they enable smarter, safer and more sustainable journeys for all. Datalytyx have deployed their DataOps for Snowflake platform to orchestrate multiple Snowflake cloud data platform tenants accessing a single primary Snowflake datastore using Snowflake Secure Data Sharing, plus Jupyter Notebooks and Tableau Online at the front end of each tenant.
"Snowflake and Datalytyx DataOps are at the heart of these new ideas for secure data sharing with our customers, and some of the new geospatial features from Snowflake will enhance this further. An initial proof of concept demonstrated how the Datalytyx thinking would complement our own, to deliver ADEPT Preview faster and more confidently than we could by ourselves. Their DataOps based approach could deliver repeatable, consistent, disposable and secure data environments for our customers in ¼ of the time."
Steve Pimblett, CIO and CDO of wejo
Snowflake Chief Technical Evangelist, Kent Graziano said “Organizations today require business agility without any sacrifices to data governance and security. Datalytyx Data Ops for Snowflake can enable customers to leverage the elastic scaling and single, integrated, secured platform benefits of Snowflake, enhanced by the CI/CD automation, audit, and governance features of this new product from Datalytyx to help achieve that business agility.”
“Snowflake delivers unique value to our customers.” said Justin Mullen, CEO of Datalytyx. “We have been working on the philosophy of DataOps and #TrueDataOps with industry pioneers for the last 12 months. #TrueDataOps has only become possible because of a number of significant and critical advancements that today are unique to Snowflake’s Cloud Data Platform. “Our DataOps for Snowflake platform enables organisations to focus on value-led development of pipelines (e.g. reduce fraud, improve customer experience, increase uptake, identify opportunities, etc.) to produce analytical processes that support and enable the achievement of that value.”
About Datalytyx
Datalytyx enables organisations to deliver better data, faster, to their customers. In 2018 Datalytyx started looking at how we could reduce the time to insight, and accelerate the time to value for our customers. In 2019 we have been developing our technologies around the emerging discipline of DataOps (with a clear focus on the true principles of DevOps) and extracting value from volume in IoT data. And in 2020 we publicly shared our DataOps Philosophy (#TrueDataOps) and released our DataOps for Snowflake platform supported by our patent-pending IoT Data Compression algorithm, Datalytyx Gallium .
Datalytyx makes it easier for you to do cool, critical, valuable and smart things with data. We provide the technology, skills, and resources to deliver better data faster. Reduced risk, fewer headaches and lower overall cost.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200605005054/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KKR to Open New Office in Milan, Strengthening Long-Term Commitment to Italy28.5.2026 09:00:00 CEST | Press release
New office reflects KKR’s localisation strategy and opportunity in Italy’s evolving investment landscape KKR, a leading global investment firm, today announced plans to open an office in Milan, further strengthening its long-term commitment to Italy and expanding its local presence in one of Europe’s largest economies. The office will support the firm’s investment activity across Private Equity, Real Assets, Credit and Insurance, while deepening client partnerships and advancing the continued development of KKR’s private wealth business in Italy. Italy has been an important market for KKR for over two decades, with over €10 billion of capital deployed since 2005 across Private Equity, Real Assets and Credit. The firm’s investments include FiberCop, Europe’s first wholesale-only, open-access fibre network, Enilive, a key player in advancing Italy’s energy transition, and CMC, a sustainable packaging leader using robotics to drive innovation. These investments reflect KKR’s focus on part
Merz Therapeutics Presents New Research at World Parkinson Congress 2026, Revealing the Hidden Burden of "OFF" Episodes in Parkinson’s Disease28.5.2026 09:00:00 CEST | Press release
A new qualitative literature review provides a comprehensive model of the patient experience of OFF episodes, identifying 132 distinct motor, non-motor and quality-of-life impacts1 The research highlights OFF episode as a complex, multifaceted experience, highlighting the profound and often invisible struggles faced by people with Parkinson’s disease1 Additional analyses of levodopa inhalation powder (INBRIJA®) confirm its clinical profile as a rapid, reliable and well-tolerated on-demand treatment for OFF episodes2,3 Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new research at the World Parkinson Congress (WPC) 2026 that uncovers the multifaceted burden of "OFF" episodes in Parkinson's disease (PD). The qualitative literature review demonstrates that these episodes are not only a re-emergence of motor symptoms, but also a complex mix of debilitating motor and non-motor symptoms that impact the lives of people with Parki
Navan Strengthens European Train Offering with Swedish Rail Integration28.5.2026 09:00:00 CEST | Press release
Through a direct connection with SilverRail, Navan adds more than 20 Swedish rail carriers to its long list of European rail options Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced the addition of more than 20 Swedish rail carriers to its platform, including Sweden’s largest operators, SJ and VR. Powered by SilverRail's global rail distribution platform, the API integration unlocks access for Navan customers to domestic rail routes in Sweden, as well as many popular cross-border routes in the region, such as between Stockholm and Copenhagen. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528696890/en/ Through a direct connection with SilverRail, Navan adds more than 20 Swedish rail carriers to its long list of European rail options “We’re seeing strong momentum in Sweden,” says Michael Riegel, Chief Customer Officer at Navan. “It’s a unique economy where you have this inte
SMBC and Toshiba Jointly Develop New Equity Indices Using Advanced Quantum-Driven Technologies28.5.2026 03:00:00 CEST | Press release
Sumitomo Mitsui Banking Corporation (“SMBC”) and Toshiba Corporation (“Toshiba”) today announced the joint development of the SMBC/TOSHIBA Quantum Driven Diversified Japan Equity Index and the SMBC/TOSHIBA Quantum Driven Diversified U.S. Equity Index, new equity indices realized with advanced quantum-driven technologies. Collectively, the indices are referred to as “SMBC/TOSHIBA Quantum Diversified” (the “Indices”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519448161/en/ Toshiba’s Simulated Bifurcation Machine 1. Background and Objectives Equity investment is central to asset management, but it also carries the ever-present risk of abrupt and substantial market fluctuations driven by geopolitical developments, changes in economic policy, and other external factors. In uncertain markets, investors are constantly seeking innovations in risk diversification that can protect their assets from unexpected market shocks. SM
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 202627.5.2026 23:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy demonstrated statistically significant overall survival benefit with an unprecedented seven-month improvement in first-line HER2+ GEAOral presentation at ASCO highlights benefit regardless of PD-L1 status, including in PD-L1 <1% BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in Chicago.The HERIZON-GEA-01 clinical trial evaluated ZIIHERA® (zanidatamab) plus chemotherapy, with and without TEVIMBRA® (tislelizumab), compared with the control arm of trastuzumab plus chemotherapy as first-line treatment for advanced/metastatic HER2+ gastroesophageal adenocarcinoma (GEA). Dr. Sun Young Rha, Professor of Medical Oncology at the Yonsei Cancer Center, Yonsei Univ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom